PSİKOTROP İLAÇLARIN BRUKSİZM ETİYOLOJİSİ VE TEDAVİSİNDEKİ ETKİSİ: GÜNCEL BİLGİLER IŞIĞINDA BRUKSİZME GENEL BAKIŞ

Özkan Miloğlu; Ahmet Berhan Yılmaz; Mustafa Taha Güller; Betül Subaşı Aksakal

doi:10.17567/ataunidfd.824011

PSİKOTROP İLAÇLARIN BRUKSİZM ETİYOLOJİSİ VE TEDAVİSİNDEKİ ETKİSİ: GÜNCEL BİLGİLER IŞIĞINDA BRUKSİZME GENEL BAKIŞ

Öz

Diş gıcırdatması olarak da bilinen bruksizm, insanların yaşam kalitesini belirli oranlarda etkileyen, olağan dışı aktivite olarak karşımıza çıkmaktadır. Gün içerisinde ve/veya uyku sırasında ortaya çıkan bruksizmin multifaktöriyel etiyolojisi olduğu düşünülmektedir. Bruksizmin etiyolojisine yönelik birçok çalışma vardır ancak bu çalışmalarda belli konulara tam bir açıklık getirilememiştir. Tedavide çeşitli yöntemler uygulanır ama bruksizmin efektif tedavisinin uygulanabilmesi için asıl etkenin bulunulması gerekmektedir. Bruksizm tedavisinde kullanılan psikotrop ilaçlar olduğu gibi bruksizmi başlatan veya var olan bruksizmi indükleyen psikotrop ilaçlar da bulunmaktadır. Bu ilaçların farklı dozlarda ve sürelerde etkileri değişmektedir. Bu derlemede bruksizm etiyolojisini ve psikotrop ilaçların bruksizmi başlatma, indükleme ve tedavi etme üzerindeki etkilerini araştırdık. Böylece bruksizmi değerlendirirken veya tedavi ederken kullanılan ilaçların etkisini vurgulamaya çalıştık. Anahtar kelimeler: bruksizm, etiyoloji, tedavi, psikotrop ilaçlar THE EFFECT OF PSYCHOTROP DRUGS IN BRUXISM ETHIOLOGY AND TREATMENT: AN OVERVIEW OF BRUXISM IN THE LIGHT OF INFORMATION ABSTRACT Bruxism, also known as teeth grinding, is an unusual activity that affects people's quality of life to a certain extent. Bruxism that occurs during the day and / or during sleep is thought to have a multifactorial etiology. There are many studies on the etiology of bruxism, but certain issues have not been fully clarified in these studies. Various methods are used in the treatment, but the main factor must be found in order to apply effective treatment of bruxism. As well as psychotropic drugs used in the treatment of bruxism, there are also psychotropic drugs that initiate bruxism or induce bruxism. The effects of these drugs at different doses and durations vary. In this review, we investigated the etiology of bruxism and the effects of psychotropic drugs on initiation, induction and treatment of bruxism. Thus, we tried to emphasize the effect of drugs used in evaluating or treating bruxism. Keywords: bruxism, etiology, treatment, psychotrop drugs

Anahtar Kelimeler

Kaynakça

1. Patır Munevveroglu A, Didinen S. Çocuklarda tüm yönleriyle bruksizm. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi, 2016;16:114-9.
2. Strausz T, Ahlberg J, Lobbezoo F, Restrepo CC, Hublin C, Ahlberg K, et al. Awareness of tooth grinding and clenching from adolescence to young adulthood: a nine-year follow-up. J Oral Rehabil 2010;37(7):497-500.
3. Kuloğlu M, Ekinci O, editors. Psikiyatride Bruksizm Yeni Symposium; 2009;47(4):218-24.
4. Mısırlıoglu M, Adışen MZ. Bruksizmin tanısı, tedavisi ve görüntülenmesi üzerine yeni görüşler. Ankara Üniversitesi Diş Hekimliği Fakültesi Dergisi 2012;39(2):93-102.
5. Diniz MB, Silva RCd, Zuanon ACC. Bruksizmismo na infância: um sinal de alerta para odontopediatras e pediatras. Revista Paulista de Pediatria 2009;27(3):329-34.
6. Bader G, Lavigne G. Sleep bruksizmism; an overview of an oromandibular sleep movement disorder. Review article. Sleep Med Rev 2000;4(1):27-43.
7. Shinkai R, Santos L, Silva F, dos Santos M, editors. Prevalence of nocturnal bruksizmism in 2-11-year-old children. Rev Odontol 1998;12(1):29-37.
8. Lobbezoo F, Ahlberg J, Raphael KG, Wetselaar P, Glaros AG, Kato T, et al. International consensus on the assessment of bruksizmism: Report of a work in progress. J Oral Rehabil 2018;45(11):837-44.

9. Byrd K, Romito L, Dzemidzic M, Wong D, Talavage T. fMRI study of brain activity elicited by oral parafunctional movements. J Oral Rehabil 2009;36(5):346-61.
10. Özen NE. Temporomandibuler bozuklukların psikiyatrik yönü ve bruksizm. Klinik Psikiyatri Dergisi 2007;10(3):148-56.
11. Giraki M, Schneider C, Schafer R, Singh P, Franz M, Raab WH, et al. Correlation between stress, stress-coping and current sleep bruksizmism. Head Face Med 2010;6:2-8.
12. Mercuþ V, Scrieciu M, Popescu SM, Crãiþoiu M, Mãrãºescu P, Marinescu R. Extended case report. Bruksizmism with a history of early onset in a 25-year-old male. 2011.
13. Manfredini D, Serra-Negra J, Carboncini F, Lobbezoo F. Current concepts of bruksizmism. Int J Prosthodont 2017;30(5):437-8.
14. Castrillon EE, Exposto FG. Sleep bruksizmism and pain. Dent Clin North Am 2018;62(4):657-63.
15. Meira ECM, Ettlin D. Bruksizmism-What is missing in the new consensus definition? J Oral Rehabil 2018;45(12):921.
16. Lobbezoo F, Ahlberg J, Glaros AG, Kato T, Koyano K, Lavigne GJ, et al. Bruksizmism defined and graded: an international consensus. J Oral Rehabil 2013;40(1):2-4.
17. Fujisawa M, Kanemura K, Tanabe N, Gohdo Y, Watanabe A, Iizuka T, et al. Determination of daytime clenching events in subjects with and without self-reported clenching. J Oral Rehabil 2013;40(10):731-6.
18. Kato S, Ekuni D, Kawakami S, Mude AH, Morita M, Minagi S. Relationship between severity of periodontitis and masseter muscle activity during waking and sleeping hours. Arch Oral Biol 2018;90:13-8.
19. Lavigne G, Kato T. Usual and unusual orofacial motor activities associated with tooth wear. Int J Prosthodont 2003;16 Suppl:80-2; discussion 9-90. 20. Winocur E, Gavish A, Voikovitch M, Emodi-Perlman A, Eli I. Drugs and bruksizmism: a critical review. J Orofac Pain 2003;17(2):99-111.
21. Martynowicz H, Gac P, Brzecka A, Poreba R, Wojakowska A, Mazur G, et al. The relationship between sleep bruksizmism and obstructive sleep apnea based on polysomnographic findings. J Clin Med 2019;8(10).
22. Thorpy MJ. Classification of Sleep Disorders. Neurotherapeutics 2012;9(4):687–701.
23. Wills L, Garcia J. Parasomnias: epidemiology and management. CNS Drugs 2002;16(12):803-10. 24. Rugh JD, Harlan J. Nocturnal bruksizmism and temporomandibular disorders. Adv Neurol 1988;49:329-41.
25. Lavigne GJ, Khoury S, Abe S, Yamaguchi T, Raphael K. Bruksizmism physiology and pathology: an overview for clinicians. J Oral Rehabil 2008;35(7):476-94.
26. Kato T, Rompre P, Montplaisir JY, Sessle BJ, Lavigne GJ. Sleep bruksizmism: an oromotor activity secondary to micro-arousal. J Dent Res 2001;80(10):1940-4.
27. Klasser GD, Rei N, Lavigne GJ. Sleep bruksizmism etiology: the evolution of a changing paradigm. J Can Dent Assoc 2015;81:f2.
28. Lobbezoo F, Naeije M. Bruksizmism is mainly regulated centrally, not peripherally. J Oral Rehabil 2001;28(12):1085-91.
29. Donnarumma V, Cioffi I, Michelotti A, Cimino R, Vollaro S, Amato M. Analysis of the reliability of the ıtalian version of the oral behaviours checklist and the relationship between oral behaviours and trait anxiety in healthy individuals. J Oral Rehabil 2018;45(4):317-22.
30. Castroflorio T, Bargellini A, Rossini G, Cugliari G, Deregibus A. Sleep bruksizmism and related risk factors in adults: A systematic literature review. Arch Oral Biol 2017;83:25-32.
31. Goettems ML, Poletto-Neto V, Shqair AQ, Pinheiro RT, Demarco FF. Influence of maternal psychological traits on sleep bruksizmism in children. Int J Paediatr Dent 2017;27(6):469-75.
32. Itani O, Kaneita Y, Ikeda M, Kondo S, Yamamoto R, Osaki Y, et al. Disorders of arousal and sleep-related bruksizmism among Japanese adolescents: a nationwide representative survey. Sleep Med 2013;14(6):532-41.
33. Ohayon MM, Li KK, Guilleminault C. Risk factors for sleep bruksizmism in the general population. Chest 2001;119(1):53-61.
34. Guo H, Wang T, Niu X, Wang H, Yang W, Qiu J, et al. The risk factors related to bruksizmism in children: A systematic review and meta-analysis. Arch Oral Biol 2018;86:18-34.
35. Camparis CM, Siqueira JT. Sleep bruksizmism: clinical aspects and characteristics in patients with and without chronic orofacial pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101(2):188-93.
36. Huynh N, Kato T, Rompre PH, Okura K, Saber M, Lanfranchi PA, et al. Sleep bruksizmism is associated to micro-arousals and an increase in cardiac sympathetic activity. J Sleep Res 2006;15(3):339-46.
37. Kato T, Thie NM, Montplaisir JY, Lavigne GJ. Bruksizmism and orofacial movements during sleep. Dent Clin North Am 2001;45(4):657-84.
38. Pierce CJ, Chrisman K, Bennett ME, Close JM. Stress, anticipatory stress, and psychologic measures related to sleep bruksizmism. J Orofac Pain 1995;9(1):51-6.
39. Manfredini D, Ahlberg J, Castroflorio T, Poggio CE, Guarda-Nardini L, Lobbezoo F. Diagnostic accuracy of portable instrumental devices to measure sleep bruksizmism: a systematic literature review of polysomnographic studies. J Oral Rehabil 2014;41(11):836-42.
40. Clark GT, Ram S. Four oral motor disorders: bruksizmism, dystonia, dyskinesia and drug-induced dystonic extrapyramidal reactions. Dent Clin North Am 2007;51(1):225-43.
41. Fratto G, Manzon L. Use of psychotropic drugs and associated dental diseases. Int J Psychiatry Med 2014;48(3):185-97.
42. Marconcini S, Giammarinaro E, Cosola S, Giampietro C, Genovesi AM, Covani U, et al. Bruksizmism and Cardio Vascular diseases: a cross-sectional study. Journal of Cardiology and Therapy 2018;5(1):734-7.
43. Garrett AR, Hawley JS. SSRI-associated bruksizmism: A systematic review of published case reports. Neurol Clin Pract 2018;8(2):135-41.
44. Lobbezoo F, van Denderen RJ, Verheij JG, Naeije M. Reports of SSRI-associated bruksizmism in the family physician's office. J Orofac Pain 2001;15(4):340-6. 45. Sadock BJ, Sadock VA, Ruiz P. Comprehensive textbook of psychiatry: lippincott Williams & wilkins Philadelphia, PA; 2000.
46. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995;310(6992):1433-8.
47. Falisi G, Rastelli C, Panti F, Maglione H, Quezada Arcega R. Psychotropic drugs and bruksizmism. Expert Opin Drug Saf 2014;13(10):1319-26.
48. Ellison JM, Stanziani P. SSRI-associated nocturnal bruksizmism in four patients. J Clin Psychiatry 1993;54(11):432-4.
49. Zandifar A, Mohammadi MR, Badrfam R. Low-Dose Quetiapine in the treatment of SSRI-ınduced bruksizmism and mandibular dystonia: case series. Iran J Psychiatry 2018;13(3):227-9.
50. Uvais NA, Sreeraj VS, Sathish Kumar SV. Sertraline induced mandibular dystonia and bruksizmism. J Family Med Prim Care 2016;5(4):882-4.
51. Raveendranathan D, Rao SG. Sertraline induced acute mandibular dystonia. J Neurosci Rural Pract 2015;6(4):586-7.
52. Wise M. Citalopram-induced bruksizmism. Br J Psychiatry 2001;178:182.
53. Drapier D, Bentue-Ferrer D, Laviolle B, Millet B, Allain H, Bourin M, et al. Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze. Behav Brain Res 2007;176(2):202-9.
54. Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004;65(7):959-65.
55. Milanlioglu A. Paroxetine-induced severe sleep bruksizmism successfully treated with buspirone. Clinics (Sao Paulo). 2012;67(2):191-2.
56. Kishi Y. Paroxetine-induced bruksizmism effectively treated with tandospirone. J Neuropsychiatry Clin Neurosci 2007;19(1):90-1.
57. Brambilla P, Cipriani A, Hotopf M, Barbui C. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry 2005;38(2):69-77.
58. Fitzgerald K, Healy D. Dystonias and dyskinesias of the jaw associated with the use of SSRIs. Human Psychopharmacology: Clinical and Experimental 1995;10(3):215-9.
59. Sabuncuoglu O, Ekinci O, Berkem M. Fluoxetine-induced sleep bruksizmism in an adolescent treated with buspirone: a case report. Spec Care Dentist 2009;29(5):215-7.
60. Soyata AZ, Oflaz S. Gabapentin treatment in bruksizmism associated with fluoxetine. J Clin Psychopharmacol 2015;35(4):481-3.
61. Isa Kara M, Ertas ET, Ozen E, Atici M, Aksoy S, Erdogan MS, et al. BiteStrip analysis of the effect of fluoxetine and paroxetine on sleep bruksizmism. Arch Oral Biol 2017;80:69-74.
62. Rajan R, Sun YM. Reevaluating antidepressant selection in patients with bruksizmism and temporomandibular joint disorder. J Psychiatr Pract 2017;23(3):173-9.
63. Miyaoka T, Yasukawa R, Mihara T, Shimizu Y, Tsubouchi K, Maeda T, et al. Successful electroconvulsive therapy in major depression with fluvoxamine-induced bruksizmism. J Ect 2003;19(3):170-2.
64. Kuloglu M, Ekinci O, Caykoylu A. Venlafaxine-associated nocturnal bruksizmism in a depressive patient successfully treated with buspirone. J Psychopharmacol 2010;24(4):627-8.
65. Montgomery SA. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr 2008;13(7 Suppl 11):27-33.
66. Chang JP, Wu CC, Su KP. A case of venlafaxine-induced bruksizmism alleviated by duloxetine substitution. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(1):307.
67. Ranjan S, P SC, Prabhu S. Antidepressant-induced bruksizmism: need for buspirone? Int J Neuropsychopharmacol 2006;9(4):485-7.
68. Sahin Onat S, Malas FU. Duloxetine-induced Sleep bruksizmism in fibromyalgia successfully treated with amitriptyline. Acta Reumatol Port 2015;40(4):391-2.
69. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159(11):1896-901.
70. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009;11(3):203-26.
71. Mendhekar D, Lohia D. Worsening of bruksizmism with atomoxetine: a case report. World J Biol Psychiatry 2009;10(4 Pt 2):671-2.
72. Yuce M, Karabekiroglu K, Say GN, Mujdeci M, Oran M. Buspirone use in the treatment of atomoxetine-induced bruksizmism. J Child Adolesc Psychopharmacol 2013;23(9):634-5.
73. Bahali K, Yalcin O, Avci A. Atomoxetine-induced wake-time teeth clenching and sleep bruksizmism in a child patient. Eur Child Adolesc Psychiatry 2014;23(12):1233-5.
74. Bilac O, Percinel I, Kavurma C. Atomoxetine-related bruksizmism in a 7-year-old boy: A case report. Indian J Psychiatry 2020;62(1):104-5.
75. Detweiler MB, Harpold GJ. Bupropion-induced acute dystonia. Ann Pharmacother 2002;36(2):251-4.
76. Qin B, Zhang Y, Zhou X, Cheng P, Liu Y, Chen J, et al. Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: a meta-analysis of efficacy and acceptability. Clin Ther 2014;36(7):1087-95.
77. Raigrodski AJ, Mohamed SE, Gardiner DM. The effect of amitriptyline on pain intensity and perception of stress in bruksizmers. J Prosthodont 2001;10(2):73-7. 78. Ware JC, Rugh JD. Destructive bruksizmism: sleep stage relationship. Sleep 1988;11(2):172-81.
79. Mohamed SE, Christensen LV, Penchas J. A randomized double-blind clinical trial of the effect of amitriptyline on nocturnal masseteric motor activity (sleep bruksizmism). Cranio 1997;15(4):326-32.
80. Raigrodski AJ, Christensen LV, Mohamed SE, Gardiner DM. The effect of four-week administration of amitriptyline on sleep bruksizmism. A double-blind crossover clinical study. Cranio 2001;19(1):21-5.
81. Vandenberg CM. MAOIs and transdermal delivery. J Clin Psychiatry 2012;73(9):e28.
82. Baker GB, Coutts RT, McKenna KF, Sherry-McKenna RL. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J Psychiatry Neurosci 1992;17(5):206-14.
83. Serra-Negra JM, Lobbezoo F, Martins CC, Stellini E, Manfredini D. Prevalence of sleep bruksizmism and awake bruksizmism in different chronotype profiles: Hypothesis of an association. Med Hypotheses 2017;101:55-8.
84. Manfredini D, Lobbezoo F. Role of psychosocial factors in the etiology of bruksizmism. J Orofac Pain 2009;23(2):153-66.
85. Manfredini D, Arreghini A, Lombardo L, Visentin A, Cerea S, Castroflorio T, et al. Assessment of anxiety and coping features in bruksizmers: A portable electromyographic and electrocardiographic study. J Oral Facial Pain Headache 2016;30(3):249-54.
86. Mostafavi SN, Jafari A, Hoseini SG, Khademian M, Kelishadi R. The efficacy of low and moderate dosage of diazepam on sleep bruksizmism in children: A randomized placebo-controlled clinical trial. J Res Med Sci 2019;24:8.
87. Saletu A, Parapatics S, Saletu B, Anderer P, Prause W, Putz H, et al. On the pharmacotherapy of sleep bruksizmism: placebo-controlled polysomnographic and psychometric studies with clonazepam. Neuropsychobiology 2005;51(4):214-25.
88. Saletu A, Parapatics S, Anderer P, Matejka M, Saletu B. Controlled clinical, polysomnographic and psychometric studies on differences between sleep bruksizmers and controls and acute effects of clonazepam as compared with placebo. Eur Arch Psychiatry Clin Neurosci 2010;260(2):163-74.
89. Sakai T, Kato T, Yoshizawa S, Suganuma T, Takaba M, Ono Y, et al. Effect of clonazepam and clonidine on primary sleep bruksizmism: a double-blind, crossover, placebo-controlled trial. J Sleep Res 2017;26(1):73-83.
90. Montgomery M. Effect of diazepam on nocturnal masticatory muscle activity. J Dent Res 1986;65:96.
91. Johar SQ. A case of sleep bruksizmism treated through behavioural change using hypnosis. Medical Journal of Dr DY Patil University. 2012;5(2):154.
92. Romanelli F, Adler DA, Bungay KM. Possible paroxetine-induced bruksizmism. Ann Pharmacother 1996;30(11):1246-8.
93. Bostwick JM, Jaffee MS. Buspirone as an antidote to SSRI-induced bruksizmism in 4 cases. J Clin Psychiatry 1999;60(12):857-60.
94. Jaffee MS, Bostwick JM. Buspirone as an antidote to venlafaxine-induced bruksizmism. Psychosomatics 2000;41(6):535-6.
95. Pavlovic ZM. Buspirone to improve compliance in venlafaxine-induced movement disorder. Int J Neuropsychopharmacol 2004;7(4):523-4.

Ayrıntılar

Birincil Dil

Türkçe

Konular

Diş Hekimliği

Bölüm

Derleme

Yazarlar

Özkan Miloğlu Bu kişi benim
0000-0002-3826-8606
Andorra

Ahmet Berhan Yılmaz Bu kişi benim
0000-0002-6276-5258
Andorra

Mustafa Taha Güller Bu kişi benim
0000-0003-0790-4961
Andorra

Betül Subaşı Aksakal Bu kişi benim
0000-0002-8389-9677
Andorra

Yayımlanma Tarihi

15 Şubat 2022

Gönderilme Tarihi

28 Mayıs 2020

Kabul Tarihi

10 Kasım 2020

Yayımlandığı Sayı

Yıl 2022 Cilt: 32 Sayı: 1

DOI

https://doi.org/10.17567/ataunidfd.824011

IZ

https://izlik.org/JA83PW99DT

Kaynak Göster

RIS / Bibtex

APA

Miloğlu, Ö., Yılmaz, A. B., Güller, M. T., & Subaşı Aksakal, B. (2022). PSİKOTROP İLAÇLARIN BRUKSİZM ETİYOLOJİSİ VE TEDAVİSİNDEKİ ETKİSİ: GÜNCEL BİLGİLER IŞIĞINDA BRUKSİZME GENEL BAKIŞ. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi, 32(1), 108-113. https://doi.org/10.17567/ataunidfd.824011

AMA

1.Miloğlu Ö, Yılmaz AB, Güller MT, Subaşı Aksakal B. PSİKOTROP İLAÇLARIN BRUKSİZM ETİYOLOJİSİ VE TEDAVİSİNDEKİ ETKİSİ: GÜNCEL BİLGİLER IŞIĞINDA BRUKSİZME GENEL BAKIŞ. Ata Diş Hek Fak Derg. 2022;32(1):108-113. doi:10.17567/ataunidfd.824011

Chicago

Miloğlu, Özkan, Ahmet Berhan Yılmaz, Mustafa Taha Güller, ve Betül Subaşı Aksakal. 2022. “PSİKOTROP İLAÇLARIN BRUKSİZM ETİYOLOJİSİ VE TEDAVİSİNDEKİ ETKİSİ: GÜNCEL BİLGİLER IŞIĞINDA BRUKSİZME GENEL BAKIŞ”. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi 32 (1): 108-13. https://doi.org/10.17567/ataunidfd.824011.

EndNote

Miloğlu Ö, Yılmaz AB, Güller MT, Subaşı Aksakal B (01 Şubat 2022) PSİKOTROP İLAÇLARIN BRUKSİZM ETİYOLOJİSİ VE TEDAVİSİNDEKİ ETKİSİ: GÜNCEL BİLGİLER IŞIĞINDA BRUKSİZME GENEL BAKIŞ. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi 32 1 108–113.

IEEE

[1]Ö. Miloğlu, A. B. Yılmaz, M. T. Güller, ve B. Subaşı Aksakal, “PSİKOTROP İLAÇLARIN BRUKSİZM ETİYOLOJİSİ VE TEDAVİSİNDEKİ ETKİSİ: GÜNCEL BİLGİLER IŞIĞINDA BRUKSİZME GENEL BAKIŞ”, Ata Diş Hek Fak Derg, c. 32, sy 1, ss. 108–113, Şub. 2022, doi: 10.17567/ataunidfd.824011.

ISNAD

Miloğlu, Özkan - Yılmaz, Ahmet Berhan - Güller, Mustafa Taha - Subaşı Aksakal, Betül. “PSİKOTROP İLAÇLARIN BRUKSİZM ETİYOLOJİSİ VE TEDAVİSİNDEKİ ETKİSİ: GÜNCEL BİLGİLER IŞIĞINDA BRUKSİZME GENEL BAKIŞ”. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi 32/1 (01 Şubat 2022): 108-113. https://doi.org/10.17567/ataunidfd.824011.

JAMA

1.Miloğlu Ö, Yılmaz AB, Güller MT, Subaşı Aksakal B. PSİKOTROP İLAÇLARIN BRUKSİZM ETİYOLOJİSİ VE TEDAVİSİNDEKİ ETKİSİ: GÜNCEL BİLGİLER IŞIĞINDA BRUKSİZME GENEL BAKIŞ. Ata Diş Hek Fak Derg. 2022;32:108–113.

MLA

Miloğlu, Özkan, vd. “PSİKOTROP İLAÇLARIN BRUKSİZM ETİYOLOJİSİ VE TEDAVİSİNDEKİ ETKİSİ: GÜNCEL BİLGİLER IŞIĞINDA BRUKSİZME GENEL BAKIŞ”. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi, c. 32, sy 1, Şubat 2022, ss. 108-13, doi:10.17567/ataunidfd.824011.

Vancouver

1.Özkan Miloğlu, Ahmet Berhan Yılmaz, Mustafa Taha Güller, Betül Subaşı Aksakal. PSİKOTROP İLAÇLARIN BRUKSİZM ETİYOLOJİSİ VE TEDAVİSİNDEKİ ETKİSİ: GÜNCEL BİLGİLER IŞIĞINDA BRUKSİZME GENEL BAKIŞ. Ata Diş Hek Fak Derg. 01 Şubat 2022;32(1):108-13. doi:10.17567/ataunidfd.824011

Cited By

Evaluation of Hounsfield Unit Value and Radiomorpometric Indexs in Panoramic Radiographs of Patients with Bruxism

Harran Üniversitesi Tıp Fakültesi Dergisi

https://doi.org/10.35440/hutfd.1320900